TriangleHEALTH PROFESSIONAL · SOURCE READING
Immunotherapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
One completed trial showed no benefit to adding atezolizumab to postoperative chemotherapy.
Evidence (postoperative atezolizumab):
In the ALEXANDRA/IMpassion030 trial (NCT03498716), 2,199 women who had not received preoperative systemic therapy were randomly assigned postoperatively to receive chemotherapy with or without atezolizumab. The chemotherapy regimen included paclitaxel and cyclophosphamide with doxorubicin or epirubicin. The primary end point was IDFS. Trial accrual was prematurely terminated by the data safety monitoring committee for futility.[111]
Source links and citations
In the ALEXANDRA/IMpassion030 trial (NCT03498716), 2,199 women who had not received preoperative systemic therapy were randomly assigned postoperatively to receive chemotherapy with or without atezolizumab. The chemotherapy regimen included paclitaxel and cyclophosphamide with doxorubicin or epirubicin. The primary end point was IDFS. Trial accrual was prematurely terminated by the data safety monitoring committee for futility.[111]
The final analysis demonstrated no benefit in IDFS with the addition of atezolizumab (HR, 1.11; 95% CI, 0.87–1.42; P = .38).[111][Level of evidence B1]
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice